RecruitingNCT05566002

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Artificial Intelligence-Assisted Evaluation of Pulmonary Hypertension

Sponsor

Chinese Pulmonary Vascular Disease Research Group

Enrollment

2,000 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Pulmonary Hypertension Pulmonary Arterial Hypertension

Summary

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is developing and validating an artificial intelligence (AI) tool to help diagnose pulmonary hypertension — a serious condition of high blood pressure in the lungs — using routine tests like chest X-rays, electrocardiograms (ECGs), and echocardiograms (heart ultrasounds). The AI is trained using data from patients who also had a right heart catheterization (a gold-standard test that confirms the diagnosis). **You may be eligible if...** - You are 18 or older - You previously had a chest X-ray, ECG, echocardiogram, and right heart catheterization at Fuwai Hospital in Beijing **You may NOT be eligible if...** - You did not have a right heart catheterization - The quality of your test results is insufficient for analysis - Key routine test data is missing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTRight heart catheterization

RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).

Locations(1)

Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05566002

Related Trials

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

NCT017300921 location

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029119 locations

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT074819812 locations

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT0652619568 locations

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT0638842167 locations